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Abstract
Background: Numerous agencies have developed clinical practice guidelines for the management
of postmenopausal osteoporosis. The study objective was to conduct a systematic assessment of
the quality of osteoporosis guidelines produced since 1998.
Methods: Guidelines were identified by searching MEDLINE (1998+), the world wide web, known
guideline developer websites, bibliographies of retrieved guidelines, and through consultation with
content experts. Each guideline was then assessed by three independent appraisers using the
'Appraisal Instrument for Clinical Guidelines' (version 1) by Cluzeau.
Results: We identified 26 unique guidelines from 1998–2001 and 21 met our inclusion criteria. Of
the 21 guidelines reviewed, 8 were developed by medical societies, 6 by national groups, 6 by
government agencies, and 1 by an international group. Twelve of the guidelines were published, 7
were organizational reports, and 2 were accessible only from the web. Half or more of the 20 items
assessing the rigor of guideline development were met by 15% (median quality score 23%, range 5–
80%, (95% CI 16.5, 34.7)), 81% met at least half of the 12 items assessing guideline content and
context (median score 58%, range 17–83%, (95% CI 50.8, 65.5)), and none met half or more of the
items assessing guideline application (median score 0%, range 0–47%, (95% CI -0.5 to 12.6)). Eight
guidelines described the method used to assess the strength of evidence, and in 6 there was an
explicit link between recommendations and the supporting evidence. Ten guidelines were judged
not suitable for use in practice, 10 were acceptable with modification, and one was acceptable for
use without modification.
Conclusion: The methodological quality of current osteoporosis guidelines is low, although their
scores for clinical content were higher. Virtually no guidelines covered dissemination issues. Few
guidelines were judged as acceptable for use in their current format.
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Background
Clinical practice guidelines are "systematically developed
statements to assist practitioner and patient decisions
about appropriate health care for specific clinical circum-
stances" [1]. In many respects this is an ideal time to de-
velop guidelines in the management of postmenopausal
osteoporosis, since large randomized controlled trials of
various therapies with clinically important outcome
measures such as fractures have been conducted [2]. In the
past few years, numerous agencies and organizations have
developed clinical practice guidelines (CPGs) for the
management of post-menopausal osteoporosis. For the
primary care physician, it is difficult to assimilate all the
information contained in the numerous guidelines and
decide which guideline to use in clinical practice. Recent
research demonstrated that the application of two differ-
ent guidelines [3] and [4] to a cohort of women who had
sustained a fracture resulted in quite different estimates of
the proportion of women who should be treated (87.9
versus 58.9%) [5].
CPGs may have the potential to improve the use of re-
search findings and ultimately the care of patients, but
only if the guidelines are associated with rigorous devel-
opment. Special consideration should be given to the im-
plementation of guidelines, including the needs of the
users. A recent needs assessment conducted by Jaglal et al.
revealed that family physicians wanted guidelines or in-
formation aids about osteoporosis that have significant
input from family physicians [6]. Additionally, with
looming health care shortages, CPGs are increasingly used
as the basis for the rationing of resources. It is therefore
important that the guidelines are developed with method-
ological rigour, then appropriately disseminated and im-
plemented [7].
The objective of this study was to identify and conduct a
systematic assessment of the most recent postmenopausal
osteoporosis guidelines produced from 1998–2001 that
made recommendations on therapy. This process in-
volved the systematic evaluation of the quality of the
guidelines using a validated quality assessment tool [7].
Methods
Search strategy
Guidelines pertaining to postmenopausal osteoporosis
were identified by searching MEDLINE (1998+), the
world wide web, known guideline developer websites, ref-
erences of retrieved guidelines and through consultation
with content experts. We restricted the search to English
language items. Search terms included the following med-
ical headings and text words: osteoporosis practice guide-
lines, osteoporosis, consensus, consensus statements, and
osteoporosis standards. We also searched known websites
listing guidelines: such as:  [www.guideline.gov],
[www.gacguidelines.ca],  [www.cma.ca/cpgs/index.asp].
Inclusion criteria
We included those documents that had clinical recom-
mendations, that used a group process to formulate rec-
ommendations and that included a bibliography of
relevant references.
Data extraction
For each guideline, the following descriptive information
was extracted: the year of development, type of developer,
publication status (peer-reviewed or not published) stated
industry sponsorship, and clinical recommendations of
pharmaceutical and non-pharmaceutical interventions.
The standardized quality instrument used to assess the
guidelines was the 'Appraisal Instrument for Clinical
Guidelines' (version 1, 1999) by Cluzeau and colleagues
[7]. This instrument is currently widely used in the United
Kingdom and Canada, and has been shown to have ac-
ceptable reliability and criterion validity [7]. This instru-
ment uses the Yes, No and Not Sure format, consists of 37
items and is divided into 3 dimensions which assess the
adequacy of documentation (Table 1). Dimension 1 (20
items) focuses on the rigour of guideline development
and reflects attributes necessary to enhance guideline va-
lidity and reliability. It inquires about the responsibility
and endorsement of the guidelines, composition of the
development group, identification and interpretation of
the evidence, the link between the evidence and recom-
mendations, and plans to update the guideline. Dimen-
sion 2 (12 items) focuses on the context and content and
addresses attributes of reliability, applicability, flexibility
and clarity. The 12 items appraise the objectives of the
guidelines, the presentation and format, the estimated
outcomes-benefits, costs and harms. Dimension 3 (5
items) addresses the dissemination, implementation, and
monitoring of the guidelines.
We included an evaluation of the global assessment of
guidelines according to a similar strategy used in another
study [7]. Appraisers were asked whether they would
"strongly recommend this guideline for use in practice
without modifications", "recommend this guideline for
use in practice on the condition of some alterations", or
"not recommend this guideline". We also included a glo-
bal quality rating using an 11-point scale, with 0 indicat-
ing the lowest possible quality and 10 representing the
highest possible quality [8]. Where the information per-
taining to background development was lacking, we
searched listed websites and attempted to contact authors
for further details.BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/20
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Table 1: Proportion of Guidelines Meeting Quality Criteria
Quality Criteria*
% CPGs where 2 or more appraisers said "yes"
Items included in Dimension 1: Rigour of Method Development
1 Is the agency responsible for the development and/or 
endorsement of the guidelines clearly identified?
95.2
2 Was funding or other support received for developing the 
guidelines?
38.1
3 If funding or other support was received, is there evidence 
that the potential biases of the funding body(ies) were taken 
into account?
14.3
4 Is there a description of the individuals (e.g. professionals, 
interest groups – including patients) who were involved in 
the guidelines development group?
85.7
5 If so, did the group contain representatives of all key disci-
plines?
23.8
6 Is there a description of the sources of information used to 
select the evidence on which the recommendations are 
based?
5.0
7 If so, are the sources of information adequate? 5.0
8 Is there a description of the method(s) used to interpret and 
assess the strength of the evidence?
38.1
9 If so, is(are) the method(s) for rating the evidence satisfac-
tory?
23.5
10 Is there a description of the methods used to formulate the 
recommendations?
28.5
11 If so, are the methods satisfactory? 9.6
12 Is there an indication of how the views of interested parties 
not on the panel (or the consensus conference participants) 
were taken into account?
19.6
13 Is there an explicit link between the major recommendations 
and the level of supporting evidence?
28.5
14 Did the guidelines receive an independent external review 
prior to their publication/release?
28.6
15 If so, is explicit information given about methods and how 
comments were addressed?
0
16 Were the guidelines piloted? 0
17 If the guidelines were piloted, is explicit information given 
about the methods used and the results adopted?
0
18 Is there a mention of a date for reviewing or updating the 
guideline?
19.1
19 Is the body responsible for the reviewing and updating clearly 
identified?
19.0
20 Overall, have the potential biases of guideline development 
been adequately dealt with, i.e. have they attempted to mini-
mize the introduction of bias adequately?
14.3
Items included in Dimension 2: Context and Content
21 Are the reasons for developing the guidelines clearly stated? 90.5
22 Are the objectives of the guidelines clearly defined? 61.9
23 Is there a satisfactory description of the patients to which the 
guidelines are meant to apply?
81.0
24 Is there a description of the circumstances (clinical or non-
clinical) in which exceptions might be made in using the 
guidelines?
28.5
25 Is there an explicit statement of how patient preferences 
should be taken into account in applying the guidelines?
14.3
26 Do the guidelines describe the condition to be detected, 
treated, or prevented in unambiguous terms?
95.3BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/20
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Three appraisers using the Cluzeau instrument independ-
ently assessed each guideline. The three appraisers consist-
ed of a rheumatologist/epidemiologist (AC),
physiotherapist/methodologist (LW) and one of either:
geriatrician/epidemiologist (MM-S-H), geriatrician (AB)
and clinical biochemist (DO). Using the assessments, we
calculated the frequency with which the guidelines ad-
hered to each of the 37 appraisal items. Adherence was de-
fined by agreement by at least two of the three appraisers.
Next, using the values assigned by each appraiser for each
item, we calculated a summary score for each dimension:
Dimension 1 – Rigour of development, Dimension 2-
Context and content and Dimension 3-Application. A
"yes" response by an appraiser was assigned a value of 1
and all other responses 0.
Statistical analysis
The dimension quality score was derived by calculating
the mean of the appraisers' scores. Each dimension was
expressed as a score out of 100% (95% CI) so that scores
could be compared across the three dimensions.
Appraiser agreement was evaluated by calculating the per-
centage of guidelines for which the three appraisers scored
the quality of each dimension within 20 percentage
points of each other and by calculating intraclass correla-
tion coefficients (ICC) for the three dimensions. Reliabil-
ity was assessed by internal consistency (Cronbach's
alpha) of each dimension by calculating the correlation
between all items within a dimension to test to what ex-
tent they measured the same underlying concept. Pear-
son's correlation coefficients were used to evaluate the
correlation between appraisers' dimension scores and glo-
bal quality scores. Differences in mean quality were ana-
lyzed using the Mann-Whitney test. All analyses were
completed using SPSS/PC Windows version 10.0.
Results
We identified 26 unique guidelines from 1998–2001: 21
were retrieved and on assessment met our inclusion crite-
ria [3,4,9–27]. Five were excluded for the following rea-
sons: three did not include clinical recommendations or
were review articles [28–30] and two were not retrievable
[31,32]. Consultation with content experts identified sev-
en guidelines, results of a Medline search identified four
further guidelines; search of the World Wide web yielded
three guidelines, and known guideline websites yielded
six potential guidelines and review of references a further
seven guidelines. Eight of the 21 guidelines reported re-
27 Are there different possible options for management of the 
condition clearly stated in the guidelines?
90.4
28 Are the recommendations clearly presented? 85.7
29 Is there an adequate description of the health benefits that 
are likely to be gained from the recommended management?
76.2
30 Is there an adequate description of the potential harms or 
risks that may occur as a result of the recommended manage-
ment?
61.9
31 Is there an estimate of the costs or expenditures likely to 
incur from the recommended management?
33.4
32 Are the recommendations supported by the estimated bene-
fits, harms and costs of the intervention?
9.6
Items included in Dimension 3: Application
33 Does the guideline document suggest possible methods for 
dissemination and implementation?
9.6
34 Does the guideline document specify criteria for monitoring 
adherence to the guidelines?
9.6
35 Does the guideline document identify clear standards or tar-
gets for adherence to the guidelines?
4.8
36 Does the guideline document define measurable outcomes 
(e.g. health, process, economic, outcomes) that can be moni-
tored?
0
37 Does the guideline document identify key elements which 
need to be considered by local guideline groups?
0
*Items are presented in the same order as they appear in the appraisal instrument
Table 1: Proportion of Guidelines Meeting Quality Criteria (Continued)BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/20
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ceiving outside funding, and 6/8 of the guidelines ac-
knowledged funding from industry.
Twelve guidelines were published, seven were organiza-
tional reports, and two were accessible only from the web.
Guideline developers included medical societies (n = 8),
national groups (n = 6), international groups (n = 1), and
government agencies (n = 6). Table 1 presents the percent-
age of the guidelines that satisfied each of the 37 quality
criteria. Figure 1 illustrates the distribution of the guide-
lines by dimension quality score. Twenty of the 21 guide-
lines did not include patients/consumers on the
development panel. Only 11 of the 21 included family
physicians.
Half or more of the 20 items assessing the rigor of guide-
line development were met by 15% of the guidelines (me-
dian quality score 23%, (95% CI 16.5, 34.7, range 5–
80%), 81% met at least half of the 12 items assessing
guideline content and context (median score 58%, (95%
CI 50.8, 65.5), range 17–83%), and none met half or
more of the items assessing guideline application (medi-
an score 0%, (95% CI -0.5, 12.6) range 0–47%).
Table 2 presents the mean dimension quality scores for
the 21 osteoporosis CPGs. Eight guidelines described the
method used to interpret and assess the strength of evi-
dence. Six of the 21 guidelines provided an explicit link
between major recommendations and supporting evi-
dence.
The mean global quality score was 5.23 (95% CI 4.52,
5.94; median 5.33, standard deviation 1.56), suggesting
that the appraisers felt the guidelines to be of medium
quality.
The mean global assessment rating demonstrated that 11
of the 21 guidelines were recommended for use in practice
(1 without change, 10 with modifications) and 10 guide-
lines were not recommended for use in practice.
Assessment of the reliability of the guideline appraisal in-
strument showed that D1 and D3 had good internal con-
sistency, and D2 was borderline. The Cronbach's alpha
was 0.87 for rigour of guideline development, 0.64 for
context and content, and 0.71 for application.
For agreement between appraisers, the intraclass correla-
tion coefficients were 0.91 for D1, 0.63 for D2 and 0.93
for D3. The appraisers' scores were within 20 percentage
points for 95%, 67% and 100% of the guidelines for D1,
2, and 3, respectively. The Pearson's correlation coeffi-
cients between appraisers' dimension scores and their glo-
bal quality scores (0–10) were 0.71 for D1, 0.60 for D2
and 0.46 for D3, with all coefficients being significant.
The Pearson's correlation coefficients between appraisers'
dimensions scores and their overall global assessment
(recommend or not) were 0.59, 0.61 and 0.49 for D1, D2
and D3 respectively, with all coefficients being significant.
Eighteen of 21 guidelines included both pharmaceutical
and non-pharmaceutical options (fall prevention, exercise
or hip protectors). Ten of the guidelines included recom-
mendations on fall prevention, and nine included recom-
mendations on hip protectors.
There was no significant difference in the mean quality as-
sessment when analyzed according to industry funded
versus non-funded guidelines, type of publication (pub-
lished, web or report), or the type of organization. There
was no significant difference in quality according to year
of publication, although there appeared to be a trend to
improved quality from 1998 to 2001. Only 1/8 of the
guidelines that acknowledged funding gave evidence that
the potential biases were taken into account.
Discussion
The methodological quality with respect to the rigor of de-
velopment and implementation of current osteoporosis
guidelines is low, although their scores with respect to
clinical content are higher. Virtually no guidelines covered
the application/dissemination issues. In particular, they
did not define outcomes that could be monitored and
failed to identify key elements that could be monitored by
local guideline groups. Only one guideline was judged ac-
ceptable for use in its current format [4]. Clinical practice
guideline developers are usually clinicians, or methodol-
ogists who have little or no training in the behavioural
and organization sciences. Tremendous time and effort
are devoted to the development of evidence-based guide-
lines and the dissemination and implementation are of-
ten considered to be a separate component which has
only recently thought to be the jurisdiction of the CPG de-
velopers.
Our findings are similar to other published reviews of
guidelines [8,33]. We also chose to limit our study to one
clinical area and to focus on recent guidelines from 1998–
2001, recognizing that guidelines currently being devel-
oped may follow a more rigorous methodology. Our re-
sults indicate that it is important to search both the
Internet and Medline as some guidelines were only posted
on the web and that retrieving all relevant guidelines can
be a difficult task that requires a comprehensive search
strategy.
Another potential limitation is that very few of the guide-
lines encouraged patient input into the development of
CPGs. Potential benefits of including patients in the
guideline development process include incorporation ofBMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/20
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Figure 1
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Table 2: Mean Quality Scores of Osteoporosis Practice Guidelines (CPG), Maximum score = 100 for each Dimension (D)
D1 D2 D3
Guideline Developer (Ref) CPG Title Acceptable for 
use
Rigor of Devel-
opment
Context and 
Content
Implementation
American College Obstetrics Gynecol-
ogy [15]
Osteoporosis No 5 50 0
American Family Physician [26] Prevention of 
osteoporosis and 
fractures
No 5 56 0
Cdn Consensus Menopause and Oste-
oporosis [19]
Osteoporosis No 8 58 0
Hong Kong PG [10] Clinical manage-
ment guidelines 
for osteoporosis 
in Hong Kong
No 12 39 0
ASCP American Society of Consultant 
Pharmacists [16]
Diagnosis and 
Treatment of OP 
in long term care 
Facilities
Y e s 1 26 40
Israeli Centre for Technology Assess-
ment [25]
Consensus state-
ment on preven-
tion and treatment 
of osteoporosis
No 12 17 0
Finland [22] Osteoporosis: 
Diagnostics and 
pharmacotherapy
No 12 33 0
Foundation for Osteoporosis Research 
and Education [11]
Guidelines of care 
on osteoporosis 
for the primary 
care physician
Y e s 1 35 30
International Committee for Oste-
oporosis Clinical Guidelines [23]
Diagnosis and 
management of 
OP in postmeno-
pausal women: 
clinical Guidelines
No 15 47 0
Brigham & Womens Hospital [14] Osteoporosis: 
guide to preven-
tion, Diagnosis and 
Treatment
Y e s 1 57 80
Osteoporosis Coalition of New Jersey 
[12]
Recommended 
practice guide-
lines for the diag-
nosis and 
treatment of oste-
oporosis
Y e s 2 36 17
American Medical Directors Association 
[13]
Osteoporosis: 
clinical practice 
guideline
Y e s 2 37 50BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/20
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priority setting from the patient perspective, improved ad-
herence with recommendations, and reinforcement of the
shared decision-making process.
Twenty-nine percent of the guidelines acknowledged in-
volvement or support from industry. Choudry et al. con-
ducted a survey of CPG authors and found 87% had some
form of interaction with the pharmaceutical industry,
with 58% receiving financial support for research. Given
the heavy involvement of industry in the osteoporosis
field, one would anticipate that the majority of the guide-
line developers would have relationships with industry
that predated the guideline creation process. Industry has
a vested interest in supporting the recommendations of
osteoporosis guidelines, which raises concerns about in-
dustry's potential to influence the guideline development
process. Acknowledgement of the degree of support/in-
volvement with industry in guideline development is im-
portant and Choudry et al. [34] recommended that there
be a formal process for discussing these conflicts prior to
CPG development.
In addition to the goal of promoting good clinical practice
and enhancing appropriate management, another poten-
tial goal of developing clinical practice guidelines is to im-
prove the use of health care resources. However, we found
that over two-thirds of guidelines neglected to include
costs. The majority of guideline recommendations are
based on results from efficacy, not effectiveness studies
and therefore are not always useful in clinical practice
[35]. While the methodological quality of guidelines is a
prerequisite to the development of good guidelines, it is
not sufficient to ensure improvements in clinical practice.
In addition, research methodologies on the impact of ev-
idence-based guidelines in clinical practice would be val-
uable.
Educational material, including the dissemination of
practice guidelines has been shown to have little or no ef-
fect on promoting behavioural change among health pro-
fessionals [36]. In contrast, strategies that encourage the
development of a local guideline initiative have been
shown to result in an increased uptake and dissemination.
Society for Obstetrician and Gynecolo-
gists of Canada [17]
An Evidence-based 
review of the man-
agement of oste-
oporosis
No 27 44 0
National Osteoporosis Foundation [3] Osteoporosis; evi-
dence for preven-
tion, diagnosis and 
treatment and 
cost-effectiveness
Y e s 2 78 30
American Association of Clinical Endo-
crinologists [9]
Guidelines for 
clinical practice for 
prevention and 
management of 
postmenopausal 
osteoporosis
Y e s 3 26 40
NIH Consensus Statement [20] Osteoporosis Pre-
vention, Diagnosis 
and Therapy
No 32 67 0
CREST [18] Clinical Resource Efficiency 
Support Team
Guidance on the 
prevention and 
treatment of oste-
oporosis
Y e s 3 35 80
London Department of Health [21] No 35 53 40
South African Medical Journal [27] Osteoporosis 
Clinical Guideline
Y e s 5 87 20
Ontario Program of Optimal Therapeu-
tics [24]
Ontario Guide-
lines for the pre-
vention and 
treatment of oste-
oporosis
Y e s 6 16 70
Royal College of Physicians [4] Osteoporosis: 
clinical guidelines 
for prevention and 
treatment
Y e s 8 08 35 3
Table 2: Mean Quality Scores of Osteoporosis Practice Guidelines (CPG), Maximum score = 100 for each Dimension (D) (Continued)BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/20
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Only one of the osteoporosis guidelines that we reviewed
encouraged development of a local initiative [4].
Conclusions
It is clear from the results of our systematic assessment
that the developers of future osteoporosis guidelines need
to incorporate greater methodological rigor and patient
involvement into the development process. It would also
be beneficial if guideline developers could follow com-
mon standard of reporting similar to that used by CON-
SORT for RCTs [37].
The multitude of guidelines dealing with postmenopausal
osteoporosis makes it difficult for individual clinicians to
decide which guideline to follow. Perhaps greater collab-
oration and sharing of resources between developer
groups would result in fewer guidelines, but with local in-
put as appropriate. More of the resources and energy
could then be directed towards the dissemination process.
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